GlassScriptPhysician profile
Mintra Saefong
NPI 1326505280
$4,452.69
in general payments reported to CMS, 2019-2025
38 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,878 · 2022: $375 · 2023: $41.44 · 2024: $965 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,199.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,276.66 | 2021-2025 | |
| Daiichi Sankyo INC. | $472.74 | 2021-2025 | Injectafer |
| Pfizer INC. | $287.65 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.75 | 2021-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $255.67 | 2021-2025 | Spravato, Invega Sustenna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.09 | 2021 | |
| Lilly USA, LLC | $165.96 | 2021-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $111.01 | 2021-2022 | |
| Radius Health, INC. | $109.43 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $108.37 | 2021 | |
| Glaxosmithkline, LLC. | $105.15 | 2021-2024 | Shingrix, Bexsero, Arexvy |
| Astrazeneca Pharmaceuticals LP | $101.29 | 2021-2025 | Airsupra |
| Novo Nordisk INC | $88.16 | 2021-2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $87.77 | 2025 | Dexcom G6 Transmitter |
| Indivior INC. | $82.34 | 2024-2025 | Sublocade |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mintra Saefong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.